ArticleNeurochemical research2025
Ropivacaine Mediates Mitochondrial Dysfunction and Ca
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms of Local Anesthetic Toxicity: From Ion Channel Dysregulation to Mitochondrial Dysfunction and Tissue-Specific Injury.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Local anesthetics may induce spinal cord neurotoxicity. Our previous work demonstrated that intrathecal ropivacaine administration causes dysmyelination in the developing spinal cord. This study elucidates the underlying mechanisms. Following intrathecal injection of 2% ropivacaine in postnatal day 7 (PND7) rats, we observed: (1) impaired sensory function evidenced by significantly elevated mechanical and thermal pain thresholds at PND14, PND21, and PND28; and (2) dysmyelination characterized by myelin sheath thinning and increased g-ratio at PND14 and PND21. To explore the molecular mechanism, primary oligodendrocyte precursor cells (OPCs) were isolated and cultured from the spinal cord of neonatal rats. In vitro, ropivacaine dose-dependently suppressed OPCs maturation, manifested by decreased MBP expression, and inhibited spontaneous Ca²⁺ oscillations and Akt activation. These effects were ameliorated by either KCl-induced Ca²⁺ oscillation enhancement or SC79-mediated Akt activation. Notably, the protective effect of SC79 against ropivacaine-induced OPC dysmaturation was abolished by calcium chelation with EGTA, indicating Akt operates upstream of Ca²⁺ oscillations in this pathway. Mechanistically, we identified that ropivacaine-induced mitochondrial dysfunction—evidenced by morphological alterations and impaired respiratory function—stems from Akt suppression and subsequent Ca²⁺ oscillation attenuation. In vivo, SC79-mediated Akt activation mitigated both ropivacaine-induced spinal cord dysmyelination and sensory deficits of hindpaw. Collectively, our study revealed that ropivacaine mediates mitochondrial dysfunction and Ca2+ oscillations attenuation in OPCs leading to spinal dysmyelination during development by inhibiting Akt signaling, which may provide a target for preventing the developmental neurotoxicity of local anesthetics.
Indexed as
Identifiers
40471461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.